Further, tissue eosinophilia per se may not even predict response to eosinophil-targeted treatments, as illustrated in EoE where eosinophil targeting by benralizumab (anti-IL5Ra) or Siglec-8 activation has shown limited clinical efficacy despite clear proven tissue eosinophilia prior to biologic treatment and successful eosinophil reduction [88,89]. Here, IL5RA is linked to Increased total eosinophil count.